Research Paper Volume 16, Issue 3 pp 2090—2122

MAEL in human cancers and implications in prognostication and predicting benefit from immunotherapy over VEGFR/mTOR inhibitors in clear cell renal cell carcinoma: a bioinformatic analysis


Figure 4. Associations of the MAEL expression with genomic alterations, gene expression, and sensitivities to VEGFR and PI3K-AKT-mTOR inhibitors. (A) Oncoprint illustrating the association between MAEL expression and genomic indices and alterations in the TCGA-KIRC cohort. (B) Diagram of identifying the genes with expression correlated with MAEL expression in the TCGA-KIRC cohort. (C, D) Gene Ontology results of the positively correlated genes (C) and negatively correlated genes (D). (E) Gene Set Enrichment Analysis results revealing the associations between MAEL expression (high vs. low, cut-off: median) and the enrichments of VEGF- and mTOR-related genes in the TCGA-KIRC cohort. (F) MAEL expression and its associations with the half-maximal inhibitory concentration levels in the 16 ccRCC cell lines. Abbreviations: IC50=half-maximal inhibitory concentration levels, TCGA-KIRC=The Cancer Genome Atlas-Kidney Renal Clear Cell Carcinoma.